Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration§

Open Ophthalmology Journal - Netherlands
doi 10.2174/1874364101408010003
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology
Ophthalmology
2016English

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Journal of Clinical & Experimental Ophthalmology
2012English

Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up

Clinical Ophthalmology
Ophthalmology
2016English

Worsening Anatomic Outcomes Following Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Well Controlled With Ranibizumab [Corrigendum]

Clinical Ophthalmology
Ophthalmology
2017English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)

BMC Geriatrics
GerontologyGeriatrics
2010English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Effect of Mitochondrial Haplogroups on Ranibizumab Response in Neovascular Age-Related Macular Degeneration Patients: A Pilot Study

Acta Ophthalmologica
MedicineOphthalmology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy